Ocular Therapeutix (OCUL) Reports Q4 Revenues Below Estimates

Note: EPS may not be comparable

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of $, versus ($0.52) reported last year. Revenue for the quarter came in at $487 thousand versus the consensus estimate of $520 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Prenetics Global (PRE) Tops Q2 EPS by 18c
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance